title: Role of CA-125 in identification of right ventricular failure in chronic obstructive pulmonary disease.
abstract: BACKGROUND
  Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disease. Cor pulmonale, characterized by right ventricular (RV) failure, can severely influence prognosis in these patients. Hence, early recognition might be important for tailoring therapy. An old biomarker, CA-125, seems to be associated with the right heart. We aimed to show the relationship between CA-125 levels and RV failure in patients with COPD.
  
  
  OBJECTIVE
  CA-125 might be a useful biomarker in identification of RV failure in patients with COPD.
  
  
  METHODS
  Forty patients with recent exacerbation of COPD were enrolled into the study. Another 40 age- and sex-matched individuals were enrolled for comparison. Levels of CA-125 were measured in the patients during the hospital stay. The COPD patients underwent echocardiographic study on the same day. Right-ventricular parameters were evaluated, and RV failure was identified via transthoracic echocardiography.
  
  
  RESULTS
  Patients with COPD had significantly higher CA-125 levels compared with controls (median 33.94 U/mL vs 9.76 U/mL, respectively; P < 0.001). Levels of CA-125 were correlated with systolic pulmonary artery pressure (r = 0.550, P < 0.001), tricuspid annular plane systolic excursion (r = - 0.496, P = 0.001), and tricuspid lateral annulus S velocity (r = - 0.549, P = 0.002). High CA-125 levels, obtained in hospitalized patients with COPD before echocardiography, enabled identification of RV failure with a sensitivity of 89.5% and specificity of 85.7%.
  
  
  CONCLUSIONS
  The CA-125 biomarker can be used to identify COPD patients with RV failure.
authors.affiliation: Department of Cardiology, Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, Sivas, Turkey. mehmet.birhan.yilmaz@tkd.org.tr
authors.forename: Mehmet Birhan
authors.initials: MB
authors.lastname: Yilmaz
authors.forename: Ali
authors.initials: A
authors.lastname: Zorlu
authors.forename: Omer Tamer
authors.initials: OT
authors.lastname: Dogan
authors.forename: Oguz
authors.initials: O
authors.lastname: Karahan
authors.forename: Izzet
authors.initials: I
authors.lastname: Tandogan
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Akkurt
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D005260:Female; D006439:Hemodynamics; D006801:Humans; D007297:Inpatients; D016015:Logistic Models; D008297:Male; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D011237:Predictive Value of Tests; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000150:complications* / Q000000981:diagnostic imaging / Q000503:physiopathology; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D014421:Turkey; D014463:Ultrasonography; D015854:Up-Regulation; D018497:Ventricular Dysfunction, Right / Q000097:blood* / Q000000981:diagnostic imaging / Q000209:etiology / Q000503:physiopathology; D016278:Ventricular Function, Right
chemical_list: D015415:Biomarkers; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins